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Abstract
Breast cancer is the most common cancer affecting women. In the screening of women for breast cancer,
mammography is the most used imaging modality. Women with an increased risk for getting breast cancer can develop
a malignancy at a relatively young age compared to other women. The increased risk for developing breast cancer can
usually be found in a positive familial history. This positive familial history is based on a gene mutation in 5–10%
of cases. The most common gene mutations are BRCA1 and BRCA2. This risk makes it necessary to start screening
these women at a young age. Mammography, however, has proven to be less reliable in younger women because its
sensitivity is lowered due to the dense breast tissue often present in this group. MRI has a higher sensitivity for detect-
ing breast cancer compared to mammography. MRI is not influenced by the density of the breast tissue. This makes
breast MRI the best modality available for the screening of women with an increased risk for developing breast cancer.
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Introduction
Breast cancer is the most common cancer affecting
women and has an enormous impact on their health. The
incidence of breast cancer varies between countries with
the highest incidence in the United States and Northern
Europe. In the United States breast cancer makes up 30%
of all cancers in women, while in The Netherlands the
lifetime risk for a woman for developing breast cancer is
about 11% [1].
The aetiology of breast cancer is varied: inherited
genetic susceptibility, acquired genetic changes, and
effects of endogenous and exogenous environment
factors. The interactions of all these factors contribute to
the development of breast cancer.
There is limited and indirect evidence that self-
examination and physical examination can help in
decreasing mortality because tumours smaller than
10 mm will not be detected in the majority of the
cases [2].
Most breast cancers are detected with mammography
in either a screening situation or by the discovery of
a palpable breast mass. The smaller the tumour is at
detection, the better the prognosis [3].
Randomised trials have shown that screening with
mammography in the age category of 50–70 years
can reduce mortality by about 25%. However, there
is no consensus at the moment about the value of
screening younger women with mammography. One of
the reasons is the lower sensitivity of mammography
in women below the age of 50 years. This is because
young, pre-menopausal, women have denser breasts
compared to post-menopausal women, resulting in an
increased chanced that a malignancy will be missed on
mammography [4].
In a diagnostic setting, magnetic resonance imaging
(MRI) is a very sensitive tool for the detection of
breast cancer. Especially for invasive breast cancer, the
sensitivity of this imaging technique is reported to be
above 95% [5]. This sensitivity is not influenced in any
way by the amount of glandular tissue present in the
breast. However the specificity of this modality is only
moderate. The role of MRI as a screening modality has
not yet been outlined. In the literature, MRI has only been
evaluated as a screening tool for women with an increased
risk for developing breast cancer [6–8]. In this paper the
role of MRI in the screening of women with an increased
risk for developing breast cancer is discussed.
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Increased risk for breast cancer
There are two categories of women who have an
increased risk for developing breast cancer.
The first group are those with a family history of breast
cancer. Approximately 20%–30% of women with breast
cancer have a positive family history and about 20% of
these individuals have a first degree relative with breast
cancer [9]. Only about 5%–10% of all cases of breast
cancer are caused by inherited factors. The most common
gene mutations are the BRCA1 and BRCA2.
In 1990, Hall and co-workers identified chromosome
17 q 21 as the location of a susceptibility gene for early
onset breast cancer, now known as the BRCA1 gene
mutation [10]. Shortly after that Narod [11] described a
linkage between the genetic marker D17 S 74 on 17
q 21 and ovarian cancer. In two different studies the
suggestion has been made that about 3% of all breast
cancers are caused by the BRCA1 gene [12,13] and about
45% of all hereditary cases of breast cancer are caused
by the BRCA1 mutation. Mutations in the BRCA1 are
most commonly seen in Russia, followed by Israel and
Italy [14]. Women who are carriers of the BRCA1 gene
mutation have a lifetime risk (LTR) for developing breast
cancer of approximately 80%. Exogenous hormone and
carcinogen exposure are also risk-modifying factors in
this group.
Other malignancies suggested to have an increased
prevalence in these families are ovarian cancer, prostate
and colonic cancer [12]. BRCA1 associated breast
malignancies tend to have a high malignancy grade and
are often oestrogen and progesterone receptor negative.
The tumour is also highly proliferative [15]. Median age
of onset of breast cancer in this group is younger than 45
years [16].
Approximately 35% of all inherited breast cancers
are caused by the BRCA2 mutation, first identified
by Wooster et al. [17]. They also described a linkage
between BRCA2 mutation and male breast cancer. The
estimated LTR for developing breast cancer in this group
is somewhat lower than in the BRCA1 group. It has
been suggested by Ursin [18] that in this group the use of
oral contraceptives also increases the risk for developing
breast cancer.
A variety of other malignancies are associated with
the BRCA2 carriers. Non-Hodgkin’s lymphoma has
been reported and also prostate cancer and bladder
cancer [19,20]. The BRCA2 mutation is associated with a
6% LTR of male breast cancer [21], which means a 100-
fold increase over the general male population. At the
moment little is known about the malignancy grade and
receptor status in the BRCA2 group [15].
For both the BRCA1 and BRCA2 mutation carriers, the
LTR for a contralateral breast cancer is about 65% [15].
There are other more sporadic hereditary diseases with
an increased risk for developing breast cancer. The Li–
Fraumeni syndrome was first identified in 1969 [22]. It
is an autosomal dominant disease causing an increased
risk for developing among others breast cancer, different
types of sarcoma and leukaemia. In this group 30% of
all malignancies occur before the age of 15. Cowden’s
disease or multiple hamartoma syndrome showed an
increased risk for both benign breast disorders like
fibroadenomas and nipple malformations and breast
malignancies [23,24]. Other hereditary diseases such as
ataxia telangiectasia and the Peutz–Jeghers syndrome
(hamartomous polyps in the small bowel) and the Muir–
Torre syndrome (a variant of hereditary non-polyposis
colon cancer) also give an increased risk for breast
cancer [25].
Another group of women with an increased risk
for breast cancer consists of women who have an
individual risk factor. Patients with a history of lobular
carcinoma in situ (LCIS) have a somewhat increased
incidence of developing an invasive cancer. The National
Surgical Adjuvant Breast and Bowel Project (NSABBP)
suggested an incidence of 13 invasive malignancies in
1000 women with an LCIS [26]. In this group there is
also a risk for bilateral breast cancer. Ductal carcinoma
in situ (DCIS) also gives an increased risk for an
invasive breast malignancy. About 30% of women
not treated postoperatively with irradiation developed
an invasive malignancy after a mean interval of 6
years [27,28]. Invasive lobular carcinoma is characterized
by multifocality in the ipsilateral breast and appears to
be more often bilateral [29] than other types of invasive
malignancies [30].
In the updated results of the nurses’ Health Study, post-
or per-menopausal use of hormones showed an excess
risk for developing breast cancer in the group of women
with current or recently used hormones [31]. The risk
increased with increasing duration.
Women treated with irradiation of the chest for,
for instance, (non-)Hodgkin’s lymphoma, also have an
increased risk for developing breast cancer. The excess
risk in this category of patients is dependent on dose and
age at irradiation. The younger the age at time of exposure
to irradiation, the younger the onset of breast cancer [32].
Screening of the breast
Currently there are four possible breast screening modali-
ties: clinical examination, mammography, ultrasound and
MRI. The primary goal of breast examinations during
screening is the detection of breast cancer at an as early
stage as possible in order to reduce mortality.
Clinical examinations of the breasts and self-
examination as a screening procedure have been poorly
evaluated. There is only limited and indirect evidence
that these methods could help in decreasing mortality
due to breast cancer [2]. As mentioned, small malignant
lesions (<10 mm) will not be detected by palpation in
the majority of cases. Kriege and co-workers showed a
sensitivity of only 17.8% of clinical breast examination
in a screening setting [6].
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Figure 1 (a), (b) The mammography of a 39-year-old woman obtained during annual screening because of a
familial history of breast cancer. No abnormalities were seen. (c) The MRI examination obtained on the same
day. Strong irregular enhancement in the medial part of the left breast was detected. Pathology revealed a
DCIS grade 3.
The most used imaging tool for screening at the
moment is mammography. The sensitivity of mammog-
raphy increases with the age of the woman. The younger
the woman, the more glandular tissue there is, the
denser the breasts are, and the lower the sensitivity
of mammography. For women in the age group 40–50
sensitivity ranges from about 50% to 80%, while in the
age group over 50 the sensitivity ranges from 70% to
about 90% [33]. The sensitivity of mammography in the
case of invasive lobular carcinoma (ILC) is lower than in
women with invasive ductal carcinoma (IDC) [30].
In 1973, the breast cancer detection demonstration
project (BCDDP) was started. In the subsequent 7 years
more than 280 000 women were screened. The screening
depicted about half of all breast cancers detected in the
screened area. In addition, the distribution of stage was
more favourable in the screened population than in a
control group in that area, so overall long-term survival
was also better [34]. In 1998 in the Netherlands a mortality
reduction of 13% was reached in the age category
55–74 since the beginning of screening in 1990 with
conventional mammography [35]. Other screening trials
like the health insurance plan of New York (HIP-study)
showed a mortality reduction of 30% in the screened
group compared to the control group. Analysis of age
specific mortality reduction indicates that screening for
breast cancer has a special benefit in older women above
the age of 50 and less in the younger age group. In
addition, Tabar et al. showed that the likelihood of
dedifferentiation of a tumour is much higher in women
younger than 40 years [36]. Survival is also influenced by
both tumour grade and the size of the tumour [36,37].
There is currently no evidence that ultrasound (US) has
a role as a screening modality for breast cancer. The two
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Figure 2 (a), (b) The mammography of a 32-year-old woman obtained during annual screening because of
a proven BRCA2 gene carrier. Very dense glandular tissue was seen on mammography. (c) The MRI from the
same day. In the medial part of the right breast an irregular strong enhancing area was seen. Pathology showed
an invasive duct carcinoma.
most important roles of US are differentiation between
cystic and solid lesions in the breast and US guided
biopsy of solid breast lesions.
MRI of the breast is nowadays mostly performed
as a dynamic investigation. The most currently used
investigation technique is the FLASH 3D technique
which includes one series of images pre-contrast and
five series of images after intravenous administration
of contrast medium containing gadolinium. MR images
are evaluated according to morphology and kinetic
behaviour of the lesions [38]. Smoothly outlined round or
oval lesions tend more to be benign, while speculated
lesions are more suspicious of a malignancy. If a lesion
shows a wash out on kinetic behaviour, this is highly
suspicious for a malignancy. If there is progress in signal
intensity over time this is more characteristic for a benign
lesion [38]. Although the sensitivity of MRI for detecting
invasive breast cancer is more than 95%, the value in
detecting DCIS, especially DCIS grade I, is lower [39].
DCIS grade 3 can usually be detected on MRI (Fig. 1).
The sensitivity for DCIS is described by Orel et al. [40]
to be in the range of 75%. Three grade I DCIS were
missed. This is in comparison to the results of Boetes
et al. [41], who also described a sensitivity of about 75%
in this group. In a series of 17 patients, they missed four
cases of DICS, 3 grade I and 1 grade III. The problem
with screening with MRI is the relatively low specificity,
which means a relatively high number of false-positive
findings. Almost all women with a genetic predisposition
for developing breast cancer are younger than the age
of 50. So the value of screening with conventional
mammography is doubtful in this group of women.
Especially in young women in a screening situation it
is important to diagnose a malignancy as early as possible
to increase survival.
Kuhl was the first to describe the results of MRI
in a screening situation for women with an increased
risk for developing breast cancer [7]. A group of
192 asymptomatic and six symptomatic women were
evaluated. In the symptomatic group, MRI detected all
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malignancies. In the asymptomatic group of women, nine
malignancies were found. MRI detected all nine, whereas
mammography combined with US detected only four.
In the same year Tilanus-Linthorst described an
asymptomatic group of 109 women with a 25% or
more lifetime risk, in which 12 gene carriers also were
included. In this group MRI detected three malignancies
occult on mammography [42]. A retrospective study in
2001 by Stoutjesdijk et al., evaluated 75 women, of whom
20% were proven gene carriers. Thirteen malignancies in
this group showed a cancer on MRI while mammography
detected five [43].
In 2003, Morris and co-workers described a group
of 367 women, retrospectively. MRI detected 14 more
malignancies than mammography [44].
In 2004, the results of screening a group of 1909
women with both MRI and mammography were
described by Kriege et al. [6]. In the LTR group of 15%–
30%, the detection rate for cancer was 7.8 per 1000
women, in the LTR of 30%–50% the detection rate
was 5.4 per 1000. However, in the group of carriers
of BRCA1/2 the incidence of malignancy was 26.5 per
1000 women. The overall sensitivity for the detection of
breast cancer was 40% for mammography and 71.5% for
MRI (Fig. 2). If only the invasive cancers were taken
into account the sensitivity of mammography dropped to
33% and of MRI increased to 79%. In the MRISK study
group 43% of all invasive malignancies were smaller that
10 mm, but in two selected control groups only, 14 and
12.5%, the tumour was smaller than 10 mm. The negative
node status was also better in the MRISK group than in
both control groups with 21.4% compared to 52.4 and
56.4%, respectively.
The results for the MRISK study group are confirmed
by the MARIBS study [8]. They evaluated 649 women
with a total of 1881 screens both with mammography
and MRI. Sensitivity of mammography was 40% and for
MRI this was 77%. The combination of both imaging
techniques showed a sensitivity of 94%. The difference
in sensitivity was especially seen in the gene carrier
group. However, as stated by Liberman [45], any method
of screening for breast cancer has the potential for both
benefit and harm. Harm are the costs, anxiety, follow-up
imaging and benign biopsies. The benefit of screening
is especially the detection of a malignancy as early as
possible. This may give a mortality reduction. Although
prognosis of small breast cancers is better, the detection
of a small cancer does not guarantee an improved survival
rate. The real value of screening can only be proved by
randomized controlled trials with death as an end point.
However, this is no longer possible. The data published
to date show that screening with MRI has benefit for
the group of women at high risk for developing breast
cancer. However, if a centre proceeds to screen with MRI
it should follow technical and interpretative guidelines
and there should be the possibility of performing MR
guided biopsies [46,47].
Conclusion
In the screening of women with an increased risk for
developing breast cancer detection needs to be done at a
young age. Therefore mammography is of limited value.
Because the sensitivity of MRI is high for detecting
breast cancer and because this sensitivity is not influenced
by the amount of glandular tissue present, as with
mammography, MRI is the best modality available at this
time for the screening of women with an increased risk
for developing breast cancer.
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